• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avalon GloboCare Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    7/21/26 8:45:13 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALBT alert in real time by email
    false --12-31 0001630212 0001630212 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) July 17, 2026

     

    Change Agents Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38728   47-1685128
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (I. R. S. Employer
    Identification No.)

     

    4400 Route 9 South, Suite 3100

    Freehold, NJ 07728

    (Address of principal executive offices, including ZIP code)

     

    (732) 780-4400

    (Registrant’s telephone number, including area code)

     

    Avalon GloboCare Corp.

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, $0.0001 par value   CHGA   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On July 17, 2026, Avalon GloboCare Corp. (now known as Change Agents Corporation) (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Charter Amendment”), with the Secretary of State of the State of Delaware to change the name of the Company from “Avalon GloboCare Corp.” to “Change Agents Corporation” effective as of July 20, 2026 (the “Name Change”).

     

    Pursuant to Delaware General Corporation Law Section 242(d)(1), no stockholder approval was required for the Charter Amendment because it only related to a name change. A copy of the Charter Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    In connection with the Name Change, the Company’s trading symbol for its common stock is expected to commence trading on The Nasdaq Capital Market on July 22, 2026 under the symbol “CHGA” (the “Symbol Change”).

     

    Neither the Name Change, nor the Symbol Change, affects the rights of the Company’s stockholders, and no stockholders is required in connection with the Name Change or the Symbol Change. The CUSIP number for the Company’s common stock will remain 05344R302.

     

    Item 8.01 Other Events.

     

    On July 21, 2026, the Company issued a press release announcing, among other things, the Name Change and Symbol Change. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description of Exhibit
    3.1   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Change Agents Corporation dated July 17, 2026
    99.1   Press release dated July 21, 2026
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    -1-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 21, 2026 Change Agents Corporation
       
      /s/ Sam Knipper
      Sam Knipper
      Chief Financial Officer

     

    -2-

     

    Get the next $ALBT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALBT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lu Wenzhao

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:33:21 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Sanders Steven Andrew

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:33:01 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mathews Michael

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    7/13/26 4:31:24 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalon GloboCare Announces Strategic Transformation into Agentic AI Software Company; Rebrands as Change Agents Corp.

    Company to begin trading tomorrow under new Nasdaq ticker symbol CHGA as it advances its portfolio of agentic AI software platforms, including Beacon and Catch-Up Company is actively evaluating additional AI software opportunities in other sectors such as defense and security FREEHOLD, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of agentic artificial intelligence ("AI") software solutions, today announced its strategic transformation into an agentic artificial intelligence software company focused on developing agentic AI software-as-a-service (SaaS) applications. In connection with this transformation, the Company

    7/21/26 8:30:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon GloboCare Expands AI Product Portfolio with Planned Launch of Beacon, an Agentic Generative Engine Optimization Platform for Small Businesses

    FREEHOLD, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology innovation company developing products for high-growth health and technology markets, a developer of agentic artificial intelligence ("AI") software solutions, today announced plans to launch Beacon, a subscription-based Agentic Generative Search Optimization (GEO) platform designed to help small businesses improve their visibility across leading AI-powered search engines. The Company currently expects Beacon to launch commercially in late Q3 2026. Beacon represents the second software product within Avalon's growing portfolio of agentic AI applications and repr

    7/15/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Patrick Flannelly Highlights KetoAir™ Progress in Supporting the Nevada First Responders Holistic Health Reset Program

    FREEHOLD, N.J., June 16, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today provided an update on the Nevada POOL/PACT Holistic Health Reset program launched in collaboration with Saga Health and SpecialtyHealth, Inc. The four-month wellness initiative, which began in August 2025, was designed to support 50 first responders through a comprehensive health optimization program focused on improving metabolic, physical, and behavioral wellness outcomes. Participants in the program are util

    6/16/26 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    SEC Filings

    View All

    Avalon GloboCare Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Change Agents Corporation. (0001630212) (Filer)

    7/21/26 8:45:13 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEL AM filed by Avalon GloboCare Corp.

    DEL AM - Avalon GloboCare Corp. (0001630212) (Filer)

    7/13/26 4:57:05 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-1 filed by Avalon GloboCare Corp.

    S-1 - Avalon GloboCare Corp. (0001630212) (Filer)

    7/10/26 7:29:07 PM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Financials

    Live finance-specific insights

    View All

    Avalon GloboCare Acquires RPM Interactive, a Generative AI Software Company, in an All-Stock Transaction

    Company forms a new subsidiary, Avalon Quantum AI, LLC, in connection with the acquisition Acquisition expected to resolve Nasdaq minimum stockholders' equity deficiency RPM Interactive has developed a fully automated, generative AI powered SaaS platform for creating short-form video content FREEHOLD, N.J., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of precision diagnostic consumer products, today announced that it has acquired RPM Interactive, Inc. ("RPM"), a generative artificial intelligence ("AI") publishing and software company, in an all-stock transaction. As a result of the acquisition, the Company believes it

    12/15/25 8:30:00 AM ET
    $ALBT
    $ASPU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Other Consumer Services
    Consumer Discretionary

    Avalon's Laboratory Services MSO Acquires California-Based Medical Supply Company and Proprietary FDA-Registered External Male Catheter Device

    FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired Merlin Medical Supply ("MMS"), a profitable, well-established Home Medical Equipment ("HME") and Durable Medical Equipment ("DME") company providing acute and non-acute medical supplies in Ventura County, California. Additionally, LSM has acquired Leading Edge Innovations, LLC from the same owner. Leading Edge Innovations owns the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontine

    9/13/23 9:15:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Avalon's Laboratory Services MSO Acquires Texas Lab with Significant Potential Growth

    FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC ("LSM"), has acquired DE Laboratory LLC ("DE Labs"), which expands its penetration within Texas and provides significant potential growth opportunities for the combined company. Avalon owns a 40% interest in LSM. DE Labs is a CLIA-certified and COLA-accredited laboratory located in Houston, Texas that offers a wide range of high-quality testing, including drug testing, genetic testing, urinary testing and COVID-19 PCR testing. LSM is no

    7/24/23 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALBT
    Leadership Updates

    Live Leadership Updates

    View All

    Avalon GloboCare Appoints Seasoned AI and Finance Executive as Chief Financial Officer

    FREEHOLD, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets, today announced the appointment of Sam Knipper as Chief Financial Officer, effective June 1, 2026. Mr. Knipper succeeds Luisa Ingargiola, who has served as the Company's Chief Financial Officer since February 2017 and has been appointed as Chief Strategy Officer, where she will continue supporting the Company's long-term strategic initiatives, capital markets activities, and growth opportunities. Mr. Knipper brings

    6/4/26 8:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fusion Fuel Appoints Luisa Ingargiola to Board of Directors

    DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (NASDAQ:HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the appointment of Luisa Ingargiola to its Board of Directors, effective February 24, 2025. Ms. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain a member of the Board. She will also serve as a member of the Nominating Committee, Audit Committee, and Compensation Committee. Following Ms. Ingargiola's appointment, the Board will be comprised of six directors, four of whom have been determined by the Board to be "independent directors" under

    2/27/25 8:00:00 AM ET
    $ALBT
    $HTOO
    $VMAR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Energy

    Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific Advisory Board in Support of KetoAir Sales

    FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:ALBT), a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach their health and wellness goals through a combination of medical and lifestyle interventions related to nutrition and exercise. Dr. Cavo specialized in family medicine as an OBGYN at the Hospital of Central Connecticut and was drawn to the challenge of the obesity epid

    10/31/24 9:00:00 AM ET
    $ALBT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care